According to the theory of cancer-immunity cycle, activated T cells need to be trafficked and infiltrated into the tumor, and only when activated T cells overcome local inhibitory factors, in the tumor microenvironment (TME), they can recognize and eliminate tumor cells.29 The use of anti-VEGF-targeted drugs could enhance T-cell infiltration into the tumor and overcome the inhibition from the immune microenvironment. The gene discussed is VEGFA; the disease is cancer.